No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 0.7x · 10Y median 0.6x · 63rd percentile · as of Oct 2, 2026
Annualized revenue (TTM) · by quarter, last 15
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-03T00:15:29.228Z. Latest historical point 2026-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-03T00:15:29.228Z. Latest historical point 2026-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-03T00:15:29.228Z. Latest historical point 2026-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-03T00:15:29.228Z. Latest historical point 2026-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-03T00:15:29.228Z. Latest historical point 2024-03-13.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-03T00:15:29.228Z. Latest historical point 2026-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-03T00:15:29.228Z. Latest historical point 2026-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-03T00:15:29.228Z. Latest historical point 2026-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Fortrea Holdings Inc. (FTRE) stock was $20.00 as of Oct 2, 2026, 4:00 PM EDT, up 3.09% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +108.4% · 3-year avg -10.3%/yr
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices.
Biotechnology · Durham, NC
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 5, 2026
33 days away
EPS Estimate
0.23
Revenue Est.
$670.56M
Last Quarter Results
EPS
$0.23
vs Estimate
$0.18
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1FTRE | $1.90B | $20.00 | +3.09% | +108.44% | N/A | N/A | N/A |
| 2XRAY | $1.74B | $8.67 | -0.80% | -32.19% | -30.43% | -16.34% | vs FTRE |
| 3NTLA | $1.71B | $12.26 | +1.16% | -40.04% | -38.01% | -3.23% | vs FTRE |
| 4RXRX | $2.16B | $4.12 | +1.23% | -25.38% | -28.37% | N/A | vs FTRE |
| 5BEAM | $2.52B | $24.50 | +0.45% | -4.26% | -22.27% | N/A | vs FTRE |
| 6TMDX | $2.76B | $79.80 | +1.47% | -31.27% | +19.54% | N/A | vs FTRE |
forward FY estimate
23.78
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$678.20M
vs Estimate
$647.57M
Consensus Rating
Based on 12 analysts
Average Price Target
$20.75
+3.8% upside
Low
$13.00
Current
$20.00
High
$26.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.19 | $0.22 | $0.26 | 7 |
| Quarter ending Dec 2026 | $0.23 | $0.24 | $0.25 | 6 |
| Quarter ending Mar 2027 | $0.22 | $0.22 | $0.22 | 2 |
| Quarter ending Jun 2027 | $0.27 | $0.27 | $0.27 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.78 | $0.84 | $0.99 | 7 |
| FY 2027 | $0.88 | $1.06 | $1.28 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $667.24M | $670.56M | $673.59M | 6 |
| Quarter ending Dec 2026 | $670.65M | $675.68M | $682.54M | 6 |
| Quarter ending Mar 2027 | $661.92M | $667.46M | $673.66M | 3 |
| Quarter ending Jun 2027 | $684.14M | $689.88M | $696.28M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.64B | $2.66B | $2.67B | 9 |
| FY 2027 | $2.72B | $2.74B | $2.76B | 9 |
